{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:24:28Z","timestamp":1787775868662,"version":"build-2784847793"},"reference-count":119,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor T (CAR-T) cell therapy is an innovative and promising approach to treat cancer. Clinical trials have demonstrated remarkable results, providing hope for patients who have exhausted more traditional therapies. However, this new therapy is not without challenges, as significant side effects have been associated with it. Cytokine release syndrome (CRS) is a widely recognized and consequential side effect of CAR-T cell therapy. Neurological toxicity is another potential side effect that can cause confusion and seizures in some patients. Hematologic toxicities, such as anemia and thrombocytopenia, can increase the risk of bleeding or infection. B-cell aplasia can also occur, leading to increased vulnerability to infections. Strategies to reduce the incidence and severity of toxicities include suicide, endogenous, and exogenous switches to modulate the activity of the immune system toward cancer while minimizing toxicity. Despite the obstacles faced by CAR-T cell therapy, continuous research and development in this area offer considerable potential for improving this treatment as a more reliable and efficient method for treating cancer.<\/jats:p>","DOI":"10.4103\/abr.abr_531_23","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:22Z","timestamp":1745971222000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges"],"prefix":"10.4103","volume":"14","author":[{"given":"Maryam","family":"Golmohammadi","sequence":"first","affiliation":[{"name":"Department of Applied Cell Sciences and Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Noorbakhsh","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Universit\u00e9 du Qu\u00e9bec \u00c0 Trois-Rivi\u00e8res, Trois-Rivi\u00e8res, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kavianpour","sequence":"additional","affiliation":[{"name":"Department of Tissue Engineering and Applied Cell Sciences, School of Medicine, Qom University of Medical Sciences, Qom, Iran"},{"name":"Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01278-3","article-title":"Exosome-based immunotherapy: A promising approach for cancer treatment","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02251-7","article-title":"Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-96466-6","article-title":"Investigation of major amino acid residues of anti-norfloxacin monoclonal antibodies responsible for binding with fluoroquinolones","volume":"11","author":"Boonserm","year":"2021","journal-title":"Sci Rep"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.smim.2020.101390","article-title":"Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy","volume":"47","author":"Rashidijahanabad","year":"2020","journal-title":"Semin Immunol"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells bispecific T cells prevent B-cell antigen escape","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"R18-20250430","first-page":"2183","article-title":"CAR T cell therapy: A new era for cancer treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol Rep"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12307-018-0208-2","article-title":"Matrix metalloproteinase 8: Could it benefit the CAR-T cell therapy of solid tumors?-A-Commentary on therapeutic potential","volume":"11","author":"Mardomi","year":"2018","journal-title":"Cancer Microenviron"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-020-01038-2","article-title":"Neurologic toxicities of cancer immunotherapies: A review","volume":"20","author":"Harrison","year":"2020","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/B978-0-12-812034-7.00012-1","article-title":"CAR-T cell clinical trials experience\u2013Past, present and future","author":"Azam","year":"2020","journal-title":"Second Generation Cell and Gene-Based Therapies"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","article-title":"Chimeric antigen receptor-T cells: A pharmaceutical scope","volume":"12","author":"Hern\u00e1ndez-L\u00f3pez","year":"2021","journal-title":"Front Pharmacol"},{"key":"R24-20250430","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood.V120.21.2604.2604","article-title":"CD19-redirected chimeric antigen receptor T (CART19) cells induce a cytokine release syndrome (CRS) and induction of treatable macrophage activation syndrome (MAS) that can be managed by the IL-6 antagonist tocilizumab (toc)","volume":"120","author":"Grupp","year":"2012","journal-title":"Blood"},{"key":"R27-20250430","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/a-1291-7692","article-title":"Macrophage activation and cytokine release syndrome in COVID-19: Current updates and analysis of repurposed and investigational anti-cytokine drugs","volume":"71","author":"Iqubal","year":"2021","journal-title":"Drug Res (Stuttg)"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"R30-20250430","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"R31-20250430","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20250430","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R33-20250430","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R34-20250430","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3389\/fonc.2019.01529","article-title":"Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy","volume":"9","author":"Thakar","year":"2019","journal-title":"Front Oncol"},{"key":"R35-20250430","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"R36-20250430","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia; Chimeric antigen receptor-modified T cells for acute lymphoid leukemia; Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"R37-20250430","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"R38-20250430","first-page":"4890287","article-title":"Acute uric acid nephropathy following epileptic seizures: Case report and review","volume":"2019","author":"Patel","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"R39-20250430","doi-asserted-by":"crossref","first-page":"9276380","DOI":"10.1155\/2018\/9276380","article-title":"The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health","volume":"2018","author":"Khammissa","year":"2018","journal-title":"Biomed Res Int"},{"key":"R40-20250430","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: Current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"R41-20250430","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"R42-20250430","doi-asserted-by":"crossref","first-page":"9684909","DOI":"10.1155\/2017\/9684909","article-title":"Tumor lysis syndrome in patients with hematological malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J Oncol"},{"key":"R43-20250430","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J Cancer"},{"key":"R44-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"R45-20250430","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R46-20250430","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor\u2013modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"R47-20250430","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R48-20250430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MEG.0000000000001530","article-title":"Graft-versus-host disease after living donor liver transplantation: An unpredictable troublesome complication for liver transplant centers","volume":"32","author":"Gonultas","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R49-20250430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/biom12010075","article-title":"Resolution of inflammation in acute graft-versus-host-disease: Advances and perspectives","volume":"12","author":"Duarte","year":"2022","journal-title":"Biomolecules"},{"key":"R50-20250430","doi-asserted-by":"crossref","first-page":"011502","DOI":"10.1063\/5.0073746","article-title":"Engineering CAR T cells for enhanced efficacy and safety","volume":"6","author":"Wu","year":"2022","journal-title":"APL Bioeng"},{"key":"R51-20250430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s13577-022-00670-z","article-title":"Activation-induced cell death in CAR-T cell therapy","volume":"35","author":"Huan","year":"2022","journal-title":"Hum Cell"},{"key":"R52-20250430","article-title":"CD19-targeted CAR T cells Therapy","author":"Ventosa","year":"2020"},{"key":"R53-20250430","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12855","article-title":"The role of metabolic checkpoint regulators in B cell survival and transformation","volume":"295","author":"Jellusova","year":"2020","journal-title":"Immunol Rev"},{"key":"R54-20250430","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2018.1473368","article-title":"Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities","volume":"18","author":"Shum","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R55-20250430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"R56-20250430","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/ajhp\/zxz056","article-title":"Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist","volume":"76","author":"Blind","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"R57-20250430","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"R58-20250430","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/ijms20246223","article-title":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R59-20250430","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"R60-20250430","doi-asserted-by":"crossref","first-page":"107760","DOI":"10.1016\/j.biotechadv.2021.107760","article-title":"Non-viral transfection technologies for next-generation therapeutic T cell engineering","volume":"49","author":"Raes","year":"2021","journal-title":"Biotechnol Adv"},{"key":"R61-20250430","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"R62-20250430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"R63-20250430","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"R64-20250430","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"R65-20250430","doi-asserted-by":"crossref","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: Mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"R66-20250430","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","article-title":"Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene","volume":"9","author":"Casucci","year":"2018","journal-title":"Front Immunol"},{"key":"R67-20250430","doi-asserted-by":"crossref","first-page":"627549","DOI":"10.3389\/fonc.2021.627549","article-title":"Strategies for dodging the obstacles in CAR T cell therapy","volume":"11","author":"Safarzadeh","year":"2021","journal-title":"Front Oncol"},{"key":"R68-20250430","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.omtn.2017.03.004","article-title":"Expression of herpes simplex virus thymidine kinase\/ganciclovir by RNA trans-splicing induces selective killing of HIV-producing cells","volume":"7","author":"Ingemarsdotter","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"R69-20250430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front Pharmacol"},{"key":"R70-20250430","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jnci\/82.4.297","article-title":"Curability of tumors bearing herpes thymidine kinase genes transfered by retroviral vectors","volume":"82","author":"Moolten","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"R71-20250430","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/cgt.2010.40","article-title":"A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma","volume":"17","author":"Sangro","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"R72-20250430","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest"},{"key":"R73-20250430","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"R74-20250430","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14724","article-title":"Strategies to overcome the side effects of chimeric antigen receptor T cell therapy","volume":"1510","author":"Mirzaee","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"R75-20250430","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"R76-20250430","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"R77-20250430","doi-asserted-by":"crossref","first-page":"e82742","DOI":"10.1371\/journal.pone.0082742","article-title":"Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma","volume":"8","author":"Budde","year":"2013","journal-title":"PLoS One"},{"key":"R78-20250430","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"R79-20250430","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R80-20250430","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R81-20250430","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3892\/etm.2021.9915","article-title":"Research advances in chimeric antigen receptor-modified T-cell therapy (Review)","volume":"21","author":"Luo","year":"2021","journal-title":"Exp Ther Med"},{"key":"R82-20250430","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"R83-20250430","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: Phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"R84-20250430","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"R85-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R86-20250430","article-title":"Genetic Relationships and Therapeutic Options for Relapsed Acute Lymphoblastic Leukemia","author":"Shertzer","year":"2020"},{"key":"R87-20250430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013Driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"R88-20250430","first-page":"vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol Adv"},{"key":"R89-20250430","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","article-title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function","volume":"7","author":"Leung","year":"2022","journal-title":"Blood Adv"},{"key":"R90-20250430","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R91-20250430","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/s41467-020-15729-4","article-title":"Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"R92-20250430","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"R93-20250430","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"R94-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-0848-x","article-title":"Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation","volume":"3","author":"Yang","year":"2020","journal-title":"Commun Biol"},{"key":"R95-20250430","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"R96-20250430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"R97-20250430","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/bfgp\/elz039","article-title":"CRISPR\/Cas9 technology: Towards a new generation of improved CAR-T cells for anticancer therapies","volume":"19","author":"Ure\u00f1a-Bail\u00e9n","year":"2020","journal-title":"Brief Funct Genomics"},{"key":"R98-20250430","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief Funct Genomics"},{"key":"R99-20250430","doi-asserted-by":"crossref","first-page":"674467","DOI":"10.3389\/fcell.2021.674467","article-title":"CRISPR\/Cas9 gene-editing in cancer immunotherapy: Promoting the present revolution in cancer therapy and exploring more","volume":"9","author":"Ou","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R100-20250430","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"R101-20250430","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"R102-20250430","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"R103-20250430","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","article-title":"CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res"},{"key":"R104-20250430","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"R105-20250430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.beha.2018.04.002","article-title":"Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety","volume":"31","author":"Halim","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"R106-20250430","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule\u2013gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"R107-20250430","doi-asserted-by":"crossref","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"R108-20250430","doi-asserted-by":"crossref","first-page":"18950","DOI":"10.1038\/srep18950","article-title":"Design of chimeric antigen receptors with integrated controllable transient functions","volume":"6","author":"Juillerat","year":"2016","journal-title":"Sci Rep"},{"key":"R109-20250430","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"R110-20250430","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R111-20250430","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R112-20250430","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc"},{"key":"R113-20250430","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R114-20250430","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: Clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R115-20250430","doi-asserted-by":"crossref","first-page":"1700187","DOI":"10.1002\/mabi.201700187","article-title":"Solid tumor immunotherapy with T cell engager-armed oncolytic viruses","volume":"18","author":"Scott","year":"2018","journal-title":"Macromol Biosci"},{"key":"R116-20250430","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1002\/cam4.2336","article-title":"A good start of immunotherapy in esophageal cancer","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med"},{"key":"R117-20250430","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R118-20250430","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2217\/imt-2020-0181","article-title":"Chimeric antigen receptor T cells immunotherapy: Challenges and opportunities in hematological malignancies","volume":"12","author":"El-Khazragy","year":"2020","journal-title":"Immunotherapy"},{"key":"R119-20250430","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_531_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:44:20Z","timestamp":1787773460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_531_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_531_23","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2023-12-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}